Navigation Links
Medivation to Announce Early Positive Data from Phase 1-2 Hormone Refractory Prostate Cancer Trial and Host Conference Call and Webcast on Monday, November 5, 2007
Date:11/3/2007

SAN FRANCISCO, Nov. 3 /PRNewswire-FirstCall/ -- Medivation, Inc. (Nasdaq: MDVN) today announced that it will announce early positive data from the ongoing Phase 1-2 trial of the company's selective androgen receptor modulator, MDV3100, in hormone refractory prostate cancer before the markets open on Monday, November 5, 2007. A conference call and live webcast will be held at 8:30 a.m. Eastern Time on Monday to discuss these data.

Conference Call Details

To access the live conference call Monday, November 5, 2007 at 8:30 a.m. Eastern Time via phone, please dial 800-930-7616 from the United States and Canada or +1913-312-0684 internationally. The conference ID is 5441900. Please dial in approximately ten minutes prior to the start of the call. Individuals interested in listening to the live call via webcast may do so by visiting http://www.medivation.com and clicking on the "Investor Relations" section. A replay of the webcast will be available on the Company's website for 30 days.

About Medivation

Medivation, Inc. is a biopharmaceutical company that acquires promising technologies in the late preclinical development phase and develops them quickly and cost-effectively. Medivation's current portfolio consists of small molecule drugs in development to treat three large, unmet medical needs -- Alzheimer's disease, Huntington's disease and hormone-refractory prostate cancer. The Company intends to build and maintain a portfolio of four to six development programs at all times. For more information, please go to http://www.medivation.com.

This press release contains forward-looking statements, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve risks and uncertainties that could cause actual results to differ significantly from those projected. You are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date of this release. You are also cautioned that none of the Company's product candidates has been approved for sale, that significant additional animal and human testing is required in order to seek marketing approval for any of its product candidates, and that Medivation cannot assure you that marketing approval can be obtained for any of its product candidates. Medivation's filings with the Securities and Exchange Commission, including its Annual Report on Form 10-KSB for the year ended December 31, 2006, include more information about factors that could affect the Company's financial and operating results.


'/>"/>
SOURCE Medivation, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. OHSU Researchers Announce New Discovery
2. PM announces a new health care order for India
3. Partnership Between Diabetes India And Elsevier Announced
4. US Politicians Urge Movie Moghuls To Add Anti-Smoking Announcements
5. Ramdoss Announces Introduction of RCH-II
6. Britain Announces Third Transfusion Related Mad Cow Case
7. Gates Foundation Announces $287 Million In Grants Towards AIDS Vaccine
8. Tibet Announces the Dalai Lama’s Tour of South Americ
9. NHS announces further Cost cutting Measures
10. Indian PM Announces Of Setting Up India Study Center At Tashkent
11. PowderMed Announces Needle-Less Flu Vaccine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/20/2017)... ... September 20, 2017 , ... Mirror Mirror Beauty Boutique ... Look Awesome This Autumn with CoolSculpting®. Scheduled for Thursday, September 28th, the afternoon ... Mirror Mirror Beauty Boutique is Houston’s largest CoolSculpting provider, holding the ...
(Date:9/20/2017)... ... 20, 2017 , ... Announced that Clear Global ... services market) has entered into an agreement on September 1, 2017 with The ... is the first private Dental School to launch an online, accredited Post Graduate ...
(Date:9/20/2017)... ... September 20, 2017 , ... Compliancy Group ... compliance software, The Guard®, has helped another long-time client pass their Department of ... properly satisfy the law. , Thanks to the help of the Compliancy Group's ...
(Date:9/20/2017)... ... ... In just a short time since going on sale on Wal-Mart Stores-owned ... trying the product for the first time, and others who had already been using ... Moore, MD, for everyone from athletes at risk from multiple concussions to elderly consumers ...
(Date:9/20/2017)... ... September 20, 2017 , ... Five consumer packaged goods (CPG) products were selected ... different categories. Nopavera Plus was named to the short list in the ... West 2017 during presentations at SupplySide Central on Sept. 27 and 28 at Mandalay ...
Breaking Medicine News(10 mins):
(Date:9/1/2017)... Michael Penna , President and CEO ... for growth in his response to the July 13, ... seeking a buyer for eMDs. Penna,s company, Complete HealthCare ... Value Added Reseller and national leader in the independent ... "As the healthcare market continues to dictate consolidation, healthcare ...
(Date:8/29/2017)... ivWatch, LLC, the leading provider of continuous monitoring devices for the ... an Innovative Technology contract from Vizient, Inc., the largest member-driven health ... ... detection of peripheral IV infiltration and extravasation events ... The Innovative Technology contract was awarded to ivWatch based on ...
(Date:8/25/2017)... 2017  Innovation Zed ( www.innovationzed.com ), an Irish medtech company, today ... South Yorkshire and Bassetlaw, England . ... diabetes patients as part of a national NHS Test Bed programme exploring ... Innovation Zed ... InsulCheck Connect, a snap-on accessory for disposable insulin pen users, ...
Breaking Medicine Technology: